Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single and Multiple Escalating Doses of ODM-108: A Single Centre Study in Healthy Male Volunteers

Trial Profile

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single and Multiple Escalating Doses of ODM-108: A Single Centre Study in Healthy Male Volunteers

Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs ODM 108 (Primary) ; Midazolam
  • Indications Neuropathic pain
  • Focus Adverse reactions
  • Acronyms FIMTRIP
  • Sponsors Orion
  • Most Recent Events

    • 16 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Sep 2016.
    • 16 Aug 2016 Status changed from recruiting to discontinued.
    • 01 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top